Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

H Corominas; I Castellví; V Pomar; R Antonijoan; I Mur; L Matas; I Gich; Benito N de; A Laiz; D Castillo; L Villamarin; D Filella; AM Millán; P Domingo

doi:10.1016/j.clim.2020.108631

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

H Corominas, I Castellví, V Pomar, R Antonijoan, I Mur, L Matas, I Gich, Benito N de, A Laiz, D Castillo, L Villamarin, D Filella, AM Millán, P Domingo

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

3 Citations (Scopus)

Original language	Undefined/Unknown
Journal	Clinical immunology (Orlando, Fla.)
DOIs	https://doi.org/10.1016/j.clim.2020.108631
Publication status	Published - Nov 2020

Access to Document

10.1016/j.clim.2020.108631

Cite this

Corominas, H., Castellví, I., Pomar, V., Antonijoan, R., Mur, I., Matas, L., Gich, I., de, B. N., Laiz, A., Castillo, D., Villamarin, L., Filella, D., Millán, AM., & Domingo, P. (2020). Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clinical immunology (Orlando, Fla.). https://doi.org/10.1016/j.clim.2020.108631

Corominas, H ; Castellví, I ; Pomar, V ; Antonijoan, R ; Mur, I ; Matas, L ; Gich, I ; de, Benito N ; Laiz, A ; Castillo, D ; Villamarin, L ; Filella, D ; Millán, AM ; Domingo, P. / Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. In: Clinical immunology (Orlando, Fla.). 2020.

@article{f6a5243e0d4149c2a5f39c6d3a9f6015,

title = "Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.",

author = "H Corominas and I Castellv{\'i} and V Pomar and R Antonijoan and I Mur and L Matas and I Gich and de, {Benito N} and A Laiz and D Castillo and L Villamarin and D Filella and AM Mill{\'a}n and P Domingo",

year = "2020",

month = nov,

doi = "10.1016/j.clim.2020.108631",

language = "Indefinido/desconocido",

}

Corominas, H, Castellví, I, Pomar, V, Antonijoan, R, Mur, I, Matas, L, Gich, I, de, BN, Laiz, A, Castillo, D, Villamarin, L, Filella, D, Millán, AM & Domingo, P 2020, 'Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.', Clinical immunology (Orlando, Fla.). https://doi.org/10.1016/j.clim.2020.108631

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. / Corominas, H; Castellví, I; Pomar, V; Antonijoan, R; Mur, I; Matas, L; Gich, I; de, Benito N; Laiz, A; Castillo, D; Villamarin, L; Filella, D; Millán, AM; Domingo, P.

In: Clinical immunology (Orlando, Fla.), 11.2020.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

AU - Corominas, H

AU - Castellví, I

AU - Pomar, V

AU - Antonijoan, R

AU - Mur, I

AU - Matas, L

AU - Gich, I

AU - de, Benito N

AU - Laiz, A

AU - Castillo, D

AU - Villamarin, L

AU - Filella, D

AU - Millán, AM

AU - Domingo, P

PY - 2020/11

Y1 - 2020/11

UR - http://europepmc.org/abstract/med/33189888

U2 - 10.1016/j.clim.2020.108631

DO - 10.1016/j.clim.2020.108631

M3 - Artículo

C2 - 33189888

ER -

Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.

Access to Document

Other files and links

Cite this